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ABSTRACT
Osteonecrosis of the jaw (ONJ) is a rare, but serious drug side effect, mainly associated with the use of intravenous (iv)
bisphosphonates (BPs). The purpose of this study was to identify genetic variants associated with ONJ in patients of European
ancestry treatedwith iv BPs using whole-exome sequencing (WES). TheWES phase 1 included 44multiplemyeloma patients (22 ONJ
cases and 22 controls) and WES phase 2 included 17 ONJ patients with solid tumors. Multivariable logistic regression analysis was
performed to estimate the odds ratios (ORs) and 95% confidence intervals (CI), adjusting for age, sex, and principal components for
ancestry. Meta-analysis of WES phase 1 and 2 was performed to estimate the combined ORs. In silico analyses were then performed
to identify expression quantitative loci (eQTL) single-nucleotide polymorphisms (SNPs) that are in high linkage disequilibrium (LD)
with the top SNPs. The associations of the potentially functional SNPs were replicated and validated in an independent case-control
study of 48 patients of European ancestry treated with iv BPs (19 ONJ cases and 29 controls). The top SNPs in the exome-wide
association meta-analysis were two SNPs on chromosome 10: SIRT1 SNP rs7896005 and HERC4 SNP rs3758392 with identical OR of
0.07 (0.01–0.46; p¼ 3.83 105). In the in silico functional analyses, two promoter region SNPs (rs7894483 and rs3758391) were
identified to be in high LDwith the index SNPs and are eQTLs for SIRT1 gene in whole blood in the GTEx database. The ORs were 0.30
(0.10–0.88), 0.26 (0.12–0.55), and 0.26 (0.12–0.55) for the WES top SNP rs7896005 and two promoter SNPs rs7894483 and rs3758391,
respectively, in the replication sample. In summary, we identified the SIRT1/HERC4 locus on chromosome 10 to be associated with iv
BP-induced ONJ and two promoter SNPs that might be the potential genetic markers for this association. © 2017 The Authors.
Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
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Introduction
Osteonecrosis of the jaw (ONJ), a rare but serious drug-induced adverse effect, is one of the most feared and
debilitating side effects of anti-resorptive agents such as
nitrogen-containing bisphosphonates (BPs) and receptor acti-
vator of NF-kB ligand (RANKL) inhibitors. The main hallmark of
ONJ is the presence of area(s) of exposed bone in the mandible
and/or maxilla for at least 8 weeks, which show(s) no signs of
healing. Drug-induced ONJ was first reported in 2003, less than
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1 year after the approval of intravenous (iv) BPs such as
zoledronate and pamidronate for the prevention of skeletal-
related events (SREs) in the setting of metastatic bone
tumors.(1,2) Because ONJ was initially recognized as a serious
complication of BPs, the term “bisphosphonate-related osteo-
necrosis of the jaw (BRONJ)” was introduced to distinguish this
side effect from other spontaneous cases of ONJ.(3) With the
advent of new classes of drugs or pharmacotherapies targeting
signaling pathways that are essential for bone remodeling or
osteoclast activation and proliferation, new cases of non-
BP-induced ONJ started to emerge. In the updated guidelines
from the American Association of Oral and Maxillofacial
Surgeons (AAOMS), the term “medication-related osteonecrosis
of the jaw (MRONJ)”(4) was introduced in light of the large body
of evidence linking ONJ to non-BP drugs indicating that ONJ is
no longer considered a class adverse effect of BPs. ONJ has been
associated with other classes of drugs, including RANKL
inhibitors, vascular endothelial growth factor (VEGF) inhibitors,
as well as mammalian target of rapamycin (m-TOR) inhibitors,(5)
and more recently, adalimumab (an inhibitor for tumor necrosis
factor a, TNF-a) has also been found to be associated with
ONJ.(6)
Although more than a decade has passed since the first
reported cases of ONJ, the pathophysiology of this disease
remains elusive despite all ongoing efforts aimed at not only
deciphering its pathogenesis but also identifying the patients at
risk of developing ONJ when treated with relevant medications.
The fact that ONJ develops in aminority of patients receiving the
aforementioned drug classes suggests that genetics may
contribute to or has a role in its pathogenesis. The majority of
the published genetic association studies on ONJ were
candidate gene studies, including our own,(7) that reported
genetic association of different polymorphisms/genes with ONJ
such as COL1A1, RANK, MMP2, OPG, OPN,(7,8) PPARG,(9) aromatase
polymorphism,(10) and MHC class II polymorphisms.(11) Two
genome-wide association studies of ONJ have been published
so far. Neither of the two genes discovered (CYP2C8 and RBMS3)
has been replicated or functionally validated.(12,13) So far, there
have been no replicated or validated genetic variants associated
with risk of ONJ with compelling evidence. The purpose of this
study was to identify functional genetic variants associated with
ONJ in patients treated with iv BPs using a two-phased whole-
exome sequencing (WES) approach followed by replication/
validation in an independent study. Our hypothesis is that
genetic variants play a significant role in BP-induced ONJ in
cancer patients.
Materials and Methods
Study design and patient selection
The inclusion criteria of our study is adult patients of any age,
sex, and race who have been treated with iv BPs. The exclusion
criterion is radiation therapy. ONJ cases were adjudicated by at
least two investigators. Because ONJ is a rare adverse effect, the
best study design is the case-control study design. ONJ cases
were defined according to the AAOMS guideline.(4) The controls
were selected to match the cases based on age, sex, and race
among the patients who were treated with iv BPs but had not
developed ONJ after 24 months of treatment. These controls
were monitored to ascertain their control status. To identify
genetic variants associated with ONJ in an unbiased manner, we
have performed a two-phased WES on germline genomic DNA
samples of a case-control study of 61 patients of European
ancestry treated with iv BPs. In phase 1, we sequenced the exons
and intron/exon junctions of 44 multiple myeloma patients
treated with iv BPs including 22 ONJ cases and 22 age- and sex-
matched controls who did not develop ONJ after at least
24 months of iv BP treatment. In phase 2, we sequenced 17 ONJ
cases who were patients with solid cancers (12 breast cancer, 3
prostate cancer, 1 cervix cancer, and 1 lung cancer). These
patients were recruited from the University of Florida in
Gainesville, FL, USA (IRB#: IRB201501186), Semmelweis Univer-
sity Medical School and Dental School in Budapest, Hungary;(14)
and University of Bologna, Italy.(15) This study was conducted
according to principles of the Declaration of Helsinki. All patients
signed an informed consent at the study site.
Whole-exome sequencing and bioinformatics analysis
Genomic DNA isolated from these patients was used for WES at
Otogenetics Corporation (Norcross, GA, USA) using Human
Agilent V5, 51Mb exome kit, and Illumina Hiseq2500 sequencing
platform. Bioinformatics analysis was then performed at
University of Florida Bioinformatics Center. Briefly, the sequence
reads were aligned to the human genome (version GRCh37/
hg19) using Bowtie, version 2.2.3.(16) Sequence alignment/map
tool (SAMtools) version 1.4(17,18) was used to process the
alignments (eg, sorting and indexing), and variant calling was
performed using the Genome Analysis Toolkit (GATK)(19)
haplotype calling pipeline in multi-sample mode, according to
GATK best practices.(20,21) Identified variants were then anno-
tated for their functional effects using Annovar.(22)
Exome-wide association analysis
Variants genotype data from WES went through additional
quality control (QC) steps that were designed to identify both
problematic variants and problematic samples before associa-
tion analysis. The QC procedure included the following: sample
call rate (>95%), SNP call rate (>95%), sex/gender check,
identity by state/identity by descendant check for relatedness,
principal component analysis (PCA) using EIGENSTRAT soft-
ware(23,24) compared with self-identified race/ethnicity, and
Hardy Weinberg Equilibrium (HWE). To control for known
confounders, all association analyses were adjusted for
covariates such as age,(25–30) sex,(31) and principle components
for ancestry. Multivariable logistic regression was performed to
estimate the odds ratio (OR) and 95% confidence interval (CI) of
each variant for the development of ONJ (yes/no) using PLINK(32)
in the phase 1 and the phase 2 separately. Meta-analysis was
then performed using METAL(33) to estimate the combined ORs
of the two phases. The I2 statistics and Cochran Q test were used
to assess the heterogeneity of the studies for eachmeta-analysis.
SNPs with p< 106 was considered statistically significant,
whereas SNPs with p< 104 were considered suggestive. Power
calculation indicates that at alpha level of 106, minor allele
frequency of 30%, we have 80% power to detect ORs of 6.5 or
0.15, assuming additive mode of inheritance.
In silico analyses
In silico analyses were performed to identify expression
quantitative loci (eQTL) SNPs that are in high linkage
disequilibrium (LD) with the top SNPs. LocusZoom(34) was
used to create regional plots of the top SNPs. HaploReg v4.1,(35)
regulomeDB(36) (Version 1.1), and Genotype-Tissue Expression
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project (GTEx) database(37) were used to select the most
functionally important SNPs in high LD with top SNPs and to
check if the selected SNPs are eQTL for certain genes.
Replication/validation study
The association of top SNPs and additional SNPs identified from
in silico analyses with iv BP-induced ONJ were evaluated further
using TaqMan Genotyping Assay. The top SNPwas genotyped in
the WES phase 1 and 2 samples using Taqman as validation for
theWES genotypes and in an independent case-control study of
48 patients of European ancestry treated with iv BPs (19 ONJ
cases and 29 controls) as independent replication. The
additional SNPs identified using in silico analysis were not
captured in the WES; therefore, genotypes in all samples were
analyzed as a validation analysis of the in silico analysis. The
genotyping was performed on QuantStudio 12K Flex RealTime
PCR System according to the company’s recommendations
(Applied Biosystems, ThermoFisher, Waltham, MA, USA).
Genotype concordance of WES and Taqman genotyping was
evaluated when appropriate.
In the replication/validation phase, multivariable logistic
regression was performed to estimate the ORs and 95% CI of
each SNP adjusting for age and sex using SAS 9.4 (Cary, NC, USA).
SNPs with p< 0.05 and the same direction of effect with theWES
analysis were considered statistically significant. Meta-analysis
was then performed using METAL(33) to estimate the combined
ORs of top SNPs based on results of the three phases.
Results
Exome-wide association analysis
After the WES bioinformatics quality control and variant calling
procedures, an average of 3,667,001 SNPs per sample (min
¼ 3,441,884, max¼ 4,048,829) were identified. After additional
quality-control steps, 427,367 variants remained for further
analysis. Two samples did not cluster with the rest of samples of
European descent in the PCA analysis and therefore were
excluded in the exome-wide association analysis.
The characteristics of the 61 patients included in the WES
analysis are summarized in Table 1. Overall, the mean age of
these patients was 64 years and 56% were females. Seventy-two
percent of these patients were treated with iv BPs because of
multiple myeloma (45% stage IIA, 42% in stage IIIA, and 12%
stage IIIB based on the Durie/Salmon staging system(38)) and
19.6% because of metastatic breast cancer. According to the
AAOMS staging criteria, 47%, 33%, and 20% of the ONJ cases
were categorized as stage 1, 2, and 3, respectively. There was no
statistically significant difference in age and type of iv BPs
between those with and without ONJ (p¼ 0.14) (Table 1).
The 20 top SNPs with the p< 5 103 in WES phase 1 were
selected to be tested in WES phase 2 and only 4 SNPs (SIRT1 SNP
rs7896005, HERC4 SNP rs3758392, SV2C SNP rs10070440, and
TBCK SNP rs11938792) showed significant p values (<0.05)
(Table 2). The meta-analysis of WES phase 1 and phase 2
identified SNPs rs7896005 and rs3758392 to be associated with
lower odds of iv BP-induced ONJ with meta-analysis OR of 0.07
(95% CI 0.02–0.26; p¼ 3.8 105) (Table 2). Regional association
plots for these two top-ranked SNPs created using LocusZoom
indicated that rs7896005 is located in the SIRT1 gene and
rs3758392 in the HERC4 gene (Fig. 1). These two SNPs had
identical minor allele frequencies and p values and therefore
were both included in the following in silico analyses.
In silico analyses identified two promoter region SIRT1 SNPs
(rs3758391 and rs7894483) in high LD with SIRT1 SNP rs7896005
and HERC4 SNPrs3758392 (r2> 0.8, D’> 0.9). The GTEx expres-
sion data for SIRT1 SNPs rs7896005, rs3758391, and rs7894483
showed that these three SNPs are all eQTLs for SIRT1 gene such
that the minor allele for each SNP is associated with
increased SIRT1 gene expression in whole blood, with a p value
of 5.1 1015, 2.8 1021, and 2.8 1021, respectively
(Fig. 2A–C). The HERC4 SNP rs3758392 is also an eQTL SNP for
the SIRT1 gene in the GTEx database (p¼ 1.8 1015) (Fig. 2D).
These SNPs are all in high LD, and we opted to genotype three
SIRT1 SNPs (rs7896005, rs3758391, and rs7894483) in the
independent validation sample.
Replication/validation of SNPs associated with BP-
induced ONJ
To further validate our findings from the WES phase 1 and 2, we
genotyped the top SNPs in the WES phase 1 and 2 samples
(n¼ 61) in addition to an independent sample of 48 cancer
patients of European ancestry using TaqMan assays. For the 61
patients with both WES genotypes and TaqMan genotypes, the
results from these two platforms were 100% concordant.
The allele frequencies of these SNPs in our study were
comparable to those in the 1000 Genomes Project, and LD
between the SNPs in our patients are summarized in Table 3. The
Table 1. Whole-Exome Sequencing Samples’ Demographics of the Discovery and Validation Phases
Characteristics Total (N¼ 61) ONJ (n¼ 39) Non-ONJ (n¼ 22)
Age (years) (mean SD) 64.0 9.5 65.3 9.5 61.6 9.1
Female (%) 55.74% 58.97% 50%
White race 100% 100% 100%
Cancer type
Multiple myeloma 44 22 22
Breast cancer 12 12 0
Cervix cancer 3 3 0
Prostate cancer 1 1 0
Renal cancer 1 1 0
Intravenous bisphosphonate useda
Zoledronate 68.85% 68.42% 69.57%
Pamidronate 29.51% 29.14% 30.43%
aWhen more than one type of bisphosphonate was used, the one with the longest exposure was presented here.
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allele frequencies of the SNPs in our patients of European
ancestry were similar to those reported in the 1000 Genomes
Project. Based on the 1000 Genomes data and our own data, the
original SIRT1 SNP rs7896005 is in high LDwith the two promoter
region SNPs rs3758391 and rs7894483 in individuals of
European ancestry. The 1000 Genomes Project data also indicate
that these three SNPs are in high LD in Asians and intermediate
LD in admixed Americans but low LD (r2< 0.2) in individuals of
African ancestry (Table 3).
The characteristics of the validation sample of 48 cancer
patients of European ancestry including 19 ONJ cases and 29
non-ONJ controls treated with iv BPs are summarized in Table 4.
Fig. 1. The regional plot of SIRT1/HERC4 SNPs associated with bisphosphonate-induced ONJ in exome-wide association analysis.
Table 2. Top SNPs in the Exome-Wide Association Analysis
Discovery Replication
SNP Nearest gene CHR A1 A2 MAF OR (95%CI) p MAF OR (95%CI) p meta p
rs7896005 SIRT1 10 A G 0.35 0.07 (0.01–0.40) 2.52E–03 0.35 0.07 (0.01–0.46) 0.0052 3.83E–05
rs3758392 HERC4 10 T C 0.35 0.07 (0.01–0.40) 2.52E–03 0.35 0.07 (0.01–0.46) 0.0052 3.83E–05
rs10070440 SV2C 5 G A 0.21 13.62 (2.47–75.04) 2.71E–03 0.16 11.68 (1.64–83.36) 0.0143 7.19E–05
rs11938792 TBCK 4 C A 0.19 59.42 (4.70–752.10) 1.61E–03 0.15 20.38 (1.28–324.20) 0.0328 1.79E–04
rs7931681 ACAT1 11 C A 0.24 0.11 (0.03–0.49) 3.53E–03 0.29 0.18 (0.03–1.02) 0.0522 3.12E–04
rs2252518 ACVR1B 12 A C 0.29 10.75 (2.28–50.60) 2.66E–03 0.20 4.56 (0.97–21.37) 0.0544 3.21E–04
rs11074355 TMC7 16 A G 0.46 0.08 (0.02–0.36) 9.84E–04 0.40 3.61 (0.83–15.72) 0.0877 3.38E–04
rs2304645 ICD 15 C G 0.46 5.98 (1.92–18.64) 2.06E–03 0.35 3.5 (0.88–13.91) 0.0751 4.48E–04
rs6696772 PPFIA4 1 C G 0.21 0.04 (0.01–0.27) 9.00E–04 0.29 0.31 (0.10–1.01) 0.0528 6.94E–04
rs4692549 TBC1D19 4 T C 0.40 0.15 (0.04–0.53) 2.97E–03 0.49 0.33 (0.09–1.22) 0.0961 7.46E–04
rs17854511 TMC7 16 G A 0.47 0.08 (0.02–0.39) 1.56E–03 0.39 2.90 (0.79–10.62) 0.1090 7.74E–04
rs867583 NDRG4 16 A G 0.25 10.55 (2.36–47.19) 2.06E–03 0.16 3.41 (0.64–18.09) 0.1495 1.13E–03
rs3809594 SETD6 16 T G 0.27 12.99 (2.58–65.55) 1.90E–03 0.18 3.26 (0.63–16.95) 0.1599 1.21E–03
rs8054895 CNOT1 16 G A 0.27 12.99 (2.58–65.55) 1.90E–03 0.18 3.26 (0.63–16.95) 0.1599 1.21E–03
rs28583298 TMC7 16 G A 0.45 0.06 (0.01–0.33) 1.17E–03 0.40 2.49 (0.64–9.69) 0.1879 1.41E–03
rs12051270 TMC7 16 G A 0.46 0.09 (0.02–0.41) 1.94E–03 0.40 2.59 (0.69–9.65) 0.1564 1.47E–03
rs12068167 SPATA17 1 A G 0.17 21.88 (3.18–150.60) 1.72E–03 0.09 3.51 (0.36–34.00) 0.2778 1.90E–03
rs2306413 ANXA5 4 C T 0.43 11.2 (2.70–46.46) 8.78E–04 0.35 2.14 (0.65–7.05) 0.2124 1.98E–03
rs647630 ARRB1 11 C T 0.47 12.3 (2.40–62.97) 2.60E–03 0.38 2.22 (0.65–7.58) 0.2050 4.23E–03
rs788827 LGR6 1 C T 0.42 9.74 (2.17–43.79) 2.99E–03 0.33 1.81 (0.51–6.41) 0.3578 6.92E–03
SNP¼ single-nucleotide polymorphism; CHR¼ chromosome; A1¼minor allele; A2¼major allele; MAF¼minor allele frequency; OR¼ odds ratio;
CI¼ confidence interval; p¼ p value of association analyses.
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The indication for iv BPs included multiple myeloma, breast
cancer, cervix cancer, prostate cancer, and renal cancer (Table 4).
Multivariable logistic regression analysis showed that the top
SIRT1 SNP rs7896005 was associated with lower odds for ONJ
with the OR of 0.3 (0.10–0.88; p¼ 0.003) in the validation sample
(Fig. 3A). The combined OR of SNP rs7896005 in three phases
was 0.16 (0.07–0.37; p¼ 3.9 107) (Fig. 3A).
The two promoter region SIRT1 SNPs (rs3758391 and
rs7894483) were identified by in silico analysis but not captured
in the WES analysis, therefore their associations with ONJ were
evaluated based on Taqman genotyping results in all samples
including WES phase 1 and 2 and the validation sample
(n¼ 109). Logistic regression showed that both of these SNPs
were also associated with lower odds for ONJ with identical ORs
Fig. 2. GTEx gene expression data show that the minor allele A of SIRT1 SNP rs7896005 (A), minor allele T of SIRT1 SNP rs3758391 (B), minor allele A of
SIRT1 SNP rs7894483 (C), and minor allele T of HERC4 SNP rs3758392 (D) had increased expression of SIRT1 gene in a dose-dependent manner.
Table 3. Allele Frequencies and Linkage Disequilibrium of the SIRT1 SNPs
A1 allele frequency LD (r2) with rs7896005
SNPs A1 A2 Our sample 1000 Genomes Project Our sample 1000 Genomes Project
EUR AFR Other EUR AFR AMR EAS SAS EUR EUR AFR AMR EAS
rs7896005 A G 0.32 0.87 0.5 0.35 0.94 0.53 0.84 0.58 1 1 1 1 1
rs3758391 T C 0.29 0.29 0.5 0.33 0.35 0.47 0.84 0.57 0.84 0.87 <0.2 0.69 0.95
rs7894483 A T 0.29 0.29 0.5 0.33 0.35 0.46 0.84 0.57 0.84 0.88 <0.2 0.69 0.93
SNP¼ single-nucleotide polymorphism; A1¼ allele 1, minor allele in European; A2¼ the other allele; LD¼ linkage disequilibrium; EUR¼ European;
AFR¼African; AMR¼Admixed American; EAS¼ East Asian; SAS¼ South Asian.
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and p values: OR of 0.26 (0.12–0.55; p¼ 0.0004) (Fig. 3B). The ORs
were identical due to complete LD between these two SNPs
(r2¼ 1) in our samples of European descent.
Discussion
In this study, we identified a locus on chromosome 10
including SIRT1 SNP rs7896005 and HERC4 SNP rs3758392 to
be associated with lower odds of developing ONJ among
cancer patients of European ancestry who were treated with iv
BPs for prevention of SREs. Two promoter region SIRT1 SNPs
(rs3758391 and rs7894483) were identified using in silico
analysis and, more importantly, were validated in an
independent sample. In silico analyses using GTEx database
indicated that these SNPs are eQTL SNPs regulating the
expression of the SIRT1 gene in whole blood where the
presence of the variant alleles resulted in reduced SIRT1
expression. Furthermore, LD analysis of the SIRT1 SNP
rs7896005 and HERC4 SNP rs3758392 indicated these two
SNPs are in fact different markers for the same signal or locus.
To our knowledge, there are currently no studies reported in
the literature linking the SIRT1/HERC4 locus to BP-induced ONJ.
From a functional perspective, the SIRT1 protein product,
Sirtuin 1 (Sirt1), belongs to a family of enzymes that collectively
mediate NAD dependent deacetylation of proteins, histones,
and transcription factors, thereby regulating a wide array of
biological processes that are pivotal for cell growth and
differentiation. However, the main question that has to be
addressed is whether Sirt1 plays any role in promoting bone
formation. Without delving into the intricacies of this process, it
is important to point out that it is a well-established fact that the
Wnt signaling pathway is integral to bone formation.(39)
Findings from several studies have demonstrated that there
are several ways by which Sirt1 potentiates Wnt signaling,
particularly in the bones.(40–43) To illustrate, Sirt1 via epigenetic
silencing, downregulates the expression of Wnt antagonists
such as the secreted frizzled related proteins (SFRPs) and
dickkopf (Dkk) protein, leading to increased availability of the
receptors for Wnt ligands and subsequently stimulation of the
downstream signaling pathways. Within this context, studies
have shown that inhibition of Sirt1 resulted in reduced
intracellular levels of dishevelled (dvl) proteins, which are
responsible for relaying the Wnt signal upon receptor stimula-
tion to the downstream intracellular signaling components such
as the beta-catenins. Sirt1-mediated deacetylation of b-catenin
promotes the accumulation of the latter in the nucleus and
activation of several transcription factors that are involved in
bone formation. Activation of Sirt1 as demonstrated in the study
by Shakibaei and colleagues(44) resulted in suppression of
osteoclastogenesis (osteoclast development) secondary to
inhibition of the RANK/RANK signaling pathway. Simulta-
neously, Sirt1 promoted osteogenesis or bone growth through
direct association with the Cbfa-1 transcription factor, thereby
promoting its activation (Cbfa-1) and production of bone-
specific collagen type I. A recent study demonstrated that SIRT1
is a positive regulator of the master osteoblast transcription
factor RUNX2 and treatment with a SIRT1 agonist promotes
osteoblast differentiation.(45) Finally, therapy of teriparatide, a
recombinant form of parathyroid hormone (PTH), was shown to
result in healing of ONJ patients.(46) This is particularly
interesting because Sirt1 may play a role in PTH regulation of
osteoblasts(47) and therefore osteoclasts. All of these evidence
Table 4. Demographics of the Replication Samples
Characteristics Total (N¼ 48) ONJ (n¼ 19) Non-ONJ (n¼ 29)
Age (years) (mean SD) 65.9 8.6 67.1 9.8 65.1 7.9
Female (%) 41.67% 68.42% 24.14%
White race 48 (100%) 19 (100%) 29 (100%)
Cancer type
Multiple myeloma 28 3 25
Breast cancer 12 11 1
Cervix cancer 1 1 0
Prostate cancer 6 3 3
Renal cancer 1 1 0
Fig. 3. Association of SIRT1 SNPs and bisphosphonate-induced ONJ in
cancer patients of European ancestry. (A) ORs (95% CI) of rs7896005 in
whole-exome sequencing (WES) phase 1, WES phase 2, and replication/
validation phase. Combined OR (95% CI) of rs7896005 in three phases
was calculated bymeta-analysis. (B) ORs (95%CI) of two promoter region
SIRT1 SNPs (rs3758391 and rs7894483) in all samples.
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underscores the importance of the SIRT1 gene and provides a
plausible explanation as towhy inhibition of Sirt1 or the reduced
expression of Sirt1 due to polymorphisms such as rs7896005,
rs3758391, or rs7894483 as noted in our study may predispose
patients to develop ONJ with BPs or other anti-resorptive drugs
in general. Although the SIRT1 seems to be the obvious
functional candidate in this association study, the HERC4 gene
might also be relevant. HERC4 belongs to the HERC family of
ubiquitin ligases and encodes HECT and RLD domain containing
E3 ubiquitin protein ligase 4.(48) A recent mouse study
demonstrated that ubiquitin E3 ligases, involved in protein
degradation, regulate osteoblast function.(49) Therefore, it is
plausible that HERC4might be also important in the pathophys-
iology of ONJ. Nonetheless, further analysis is warranted to
pinpoint the functional variant for this association. Most
importantly, knock-out and functional studies should be
conducted to further elucidate the role of SIRT1 in bone
formation and understand how bisphosphonates can perturb
this process and subsequently predispose patients to develop-
ment of this debilitating complication that could negatively
affect the patients’ quality of life.
It is also important to recognize that the minor allele
frequencies of and LD between these three SIRT1 SNPs vary
across race/ethnicity groups based on data from the 1000
Genomes Project. The minor allele (A) for rs7896005, which is
associated with lower odds of ONJ, has the lowest allele
frequency in individuals of European descent (35%), highest
frequency (94%) in Africans, and intermediate frequencies in
admixed Americans (53%), South Asians (58%), and East Asians
(84%), respectively. Based on these allele frequency differences
and that the minor allele was associated with lower risk for ONJ,
we would expect highest incidence of ONJ in patients of
European ancestry and lowest in those of African ancestry, and
this is exactly what we and others have observed.(7,50)
Our study has some limitations that need to be recognized. To
minimize false-positive findings potentially caused by popula-
tion stratification, we chose to analyze patients of European
ancestry alone, which further decreased our sample size and
limited the generalizability of our study result. Hence, the
association between the SIRT1 SNPs identified herein and the
development of ONJ with BPs in other racial/ethnic groups
remains elusive or unknown and warrants further investigation.
Because the haplotype structures tend to vary between races, it
is imperative that all three SIRT1 SNPs and not only rs7896005 be
interrogated particularly in patients with African ancestry where
the SNPs are in low LD (r2< 0.2). Also, because of our small
sample size, we did not have enough patients to evaluate the
genetic association with ONJ within each cancer population
such as multiple myeloma or breast cancer.
As for the implications of our findings, we believe that our
data may set the groundwork for a personalized approach with
regards to the use of BPs in the setting of SREs prevention.
Hence, to circumvent the incidence of ONJ, patients carrying the
G polymorphism for rs7896005, C polymorphism for rs3758391,
or T polymorphism for rs7894483 in SIRT1 may potentially
benefit from lower exposure or less frequent administration of
these drugs. Nonetheless, the efficacy of this strategy requires
further validation in a clinical study to ensure that the efficacy of
these drugs is not compromised. With the ever-increasing
number of pharmacotherapies causing ONJ, including denosu-
mab, VEGF inhibitors, and others, it is imperative that more
studies be conducted to uncover the genetic determinants of
drug-induced ONJ and understand how these offending agents
disrupt the signaling or biological pathways that lead to its
pathogenesis.
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